Research Groups and R&D Platforms: Basic research
R&D Platform:
Screening Unit
The screening unit offers academic researchers and industrial customers a broad range of services for identifying and optimising bioactive molecules for the drug discovery process. These include molecular modelling and in silico screening, development of screening assays and compound library screens, in vitro and in situ hit validation, hit optimisation and SAR analyses. A suite of cell and tissue-based disease models for oncology and neurological diseases are available for further validation of optimised hits or for independent phenotypic screens. High-throughput kinetic assays of changes in morphology or intracellular signalling over time may be integrated into chemical, genetic or optogenetic perturbation screens. A library of reporters in gene-delivery vectors are available for this purpose. The unit also has experience performing screens and toxicological evaluations in small animal models.
Contact details
High-throughput screens, screen-compatible assays, high-throughput microscopy, libraries, optogenetics, cell-based neurological disease models:
michael.courtney[at]utu.fi
3D oncology models, phenotypic screens, high-content screens:
malin.akerfelt[at]utu.fi
Medicinal chemistry, virtual screening and molecular modelling:
olli.pentikainen[at]utu.fi
Assay development, Basic research, Disease models, High throughput imaging, Hit to lead, Lead optimization, Medicinal chemistry, Molecular modelling, R&D Platforms, Screening, Signaling, Target discovery
Research Group:
Organic electronics
Ronald Österbacka
ronald.osterbacka[at]abo.fi
Laboratory of Physics,
Åbo Akademi University
Basic research, Physics
R&D Platform:
Center for Functional Materials (FUNMAT)
FUNMAT is a research center in functional materials based at Åbo Akademi University. FUNMAT is combining the expertise in chemistry, physics, biology, paper coating and printing to develop functional materials, devices and large area manufacturing for interfacing with biological systems. The multidisciplinary research is done in close collaboration with industry and our extensive collaboration network throughout the world.
Basic research, Biochemistry, Diagnostics, Drug delivery, Drug solubility, Formulation, Nanoparticles, Pharmacy, Physics, Preclinical development, R&D Platforms
Research Group:
Alzheimers’s disease associated with metabolic diseases / Rare diseases
Ullamari Pesonen
ullamari.pesonen[at]utu.fi
Institute of Biomedicine,
University of Turku
Basic research, Biomarker, Biomedicine, Disease models, Drug target, Inherited diseases, Metabolic diseases, Neurological disorders, Personalized medicine, Pharmacology, Target discovery
Research Group:
Novel multitargeting therapies for neurodegenerative diseases
Timo Myöhänen
timo.myohanen[at]utu.fi
Institute of Biomedicine,
University of Turku
PREP in Neurodegenerative Disorders (Helsinki-group page)
Ageing-related diseases, Assay development, Basic research, Biomedicine, Diagnostics, Disease models, Drug target, Imaging software, In Vitro Diagnostics, In Vivo Diagnostics, MALS or SEC-MALS, Medicinal chemistry, Molecular Biology, Molecular modelling, Neurological disorders, PET, Pharmacology, Signaling, Target discovery
Research Group:
Recombinant antibodies and other bioaffinity molecules
Urpo Lamminmäki
urplammi[at]utu.fi
Department of Life Technologies,
University of Turku
Antibodies, Assay development, Basic research, Biomarker, Biotechnology, Cancer, Combinatorial chemistry, Diagnostics, Drug target, Fluorescence spectroscopy, Hit to lead, In Vitro Diagnostics, Infection, Lead optimization, Metabolic diseases, Molecular Biology, Molecular modelling, Nanoparticles, Next-generation sequencing, Ovarian cancer, Point of care, Prostate cancer, Screening, Synthetic Biology, Target discovery
